Anavex life sciences to present at the btig virtual biotechnology conference 2023

New york, aug. 02, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in a fireside chat at the btig virtual biotechnology conference 2023, taking place on august 7-8, 2023.
AVXL Ratings Summary
AVXL Quant Ranking